// App-Quantinova.ai

327 : Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study.

Researchers

Presenter

  • Elizabeth R. Plimack

Principal Investigators

  • Jens Bedke

  • Frdric Pouliot

  • Viktor Stus

  • Tom Waddell

  • Rustem Gafanov

  • Dmitry Nosov

  • Boris Alekseev

  • Raymond S. McDermott

  • Maurice Markus

  • Sophie Tartas

  • Anna Kryzhanivska

  • Igor Bondarenko

  • Cezary Szczylik

  • Jianxin Lin

  • Rodolfo F. Perini

  • L. Rhoda Molife

  • Michael B. Atkins

  • Brian I. Rini

Medical Centers

  • Fox Chase Cancer Center, Philadelphia, PA

  • Barts Health and the Royal Free NHS Trusts, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Eberhard Karls University, Tubingen, Germany

  • CHU of Québec and Laval University, Québec City, ON, Canada

  • Dnipropetrovsk Medical Academy under the Ministry of Health of Ukraine, Dnipropetrovsk, Ukraine

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Russian Research Centre of Roentgenoradiology, Moscow, Russia

  • Central Clinical Hospital With Outpatient Clinic, Moscow, Russian Federation

  • Federal Medical Research Center n.a. P.A. Hertsen, Moscow, Russian Federation

  • Adelaide and Meath Hospital and Trinity College Dublin, Dublin, Ireland

  • Rocky Mountain Cancer Center, Denver, CO

  • GINECO & Centre Hospitalier Lyon-Sud, Lyon, France

  • Ivano-Frankivsk Regional Oncology Clinical Dispensary, Ivano-Frankivsk, Ukraine

  • Dnipropetrovsk City Multidisciplinary Clinical Hospital No 4, Dnipro, Ukraine

  • European Health Center Otwock & Postgraduate Medical Education Center, Warsaw, Poland

  • Merck & Co., Inc., Kenilworth, NJ

  • NCRI, London, United Kingdom

  • Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC

  • Vanderbilt-Ingram Cancer Center, Nashville, TN

Locations

  • United States

  • United Kingdom

  • Germany

  • Canada

  • Ukraine

  • Russia

  • Ireland

  • France

  • Poland

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

  • Clear cell renal carcinoma

  • Solid malignancies

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Pembrolizumab

  • Sunitinib

  • Inlyta

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02853331

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved